Clinical Significance of the NQO1 C609T Polymorphism in Non Small Cell Lung Adenocarcinoma Patients

  • Masroor, Mirza (Biochemistry, Maulana Azad Medical College) ;
  • Jain, Amit (Biochemistry, Maulana Azad Medical College) ;
  • Javid, Jamsheed (Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk) ;
  • Mir, Rashid (Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk) ;
  • Prashant, Y (Biochemistry, Maulana Azad Medical College) ;
  • Imtiyaz, A (Biochemistry, Maulana Azad Medical College) ;
  • Mariyam, Z (Biochemistry, Maulana Azad Medical College) ;
  • Mohan, Anant (Department of Pulmonary Medicine and Sleep Disorder All India Institute of Medical Sciences) ;
  • Ray, PC (Biochemistry, Maulana Azad Medical College) ;
  • Saxena, Alpana (Biochemistry, Maulana Azad Medical College)
  • Published : 2015.12.03


Background: NAD(P)H:quinone oxidoreductase 1 (NQO1) is part of the antioxidant defence system involved in detoxification. This study aimed to analyze the influence of NQO1 (C609T) genetic polymorphism in non small cell lung cancer (NSCLC)as a putative risk factor. Materials and Methods: Present study included 100 cases of NSCLC (adenocarcinoma) patients and 100 age and sex matched healthy controls. NQO1 (C609T) genotyping was performed by allele specific PCR for assessment of putative associations with clinical outcome and genotypes of. The association of the polymorphism with the survival of NSCLC patients' was analyzed by Kaplan-Meier method. Results: In Indian NSCLC (adenocarcinoma) patients increased risk of developing NSCLC was found to be associated with NQO1 609TT genotype [OR 3.68(0.90-14.98), RR 2.04(0.78-5.31)] for CT [OR 2.91(1.58-5.34), RR 1.74(1.23-2.44) p=0.0005 for CT], for CT+TT [ OR 3.26(1.82-5.82), RR 1.87(1.34-2.61) p<0.0001 for CT+TT]. A significant difference (p=0.0009) was observed in genotype distribution among cases and healthy controls. Patients with CT+TT genotype exhibited a significant poor overall survival compared with patients displaying homozygous CC genotype (p=0.03) and when survival independently compared with CC, TT and CT genotype was also found to be significantly associated (p=0.02). Overall median survival times were CT 6.0 months, TT 8.2 months, and CT + TT (6.4 months)]. Conclusions: The present study revealed that NQO1 CT, TT and CT+TT genotypes may be associated with clinical outcome and risk of developing NSCLC in the Indian population.


NSCLC patients;adenocarcioma;NQO1 gene (C609T) polymorphism;AS-PCR


  1. Anwar A, Dehn D, Siegel D, et al (2003). Interaction of human NAD (P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. J Biol Chem, 278, 10368-73.
  2. Asher G, Lotem J, Cohen B, et al (2001). Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc Natl Acad Sci USA, 98, 1188-93.
  3. Chao C, Zhang ZF, Berthiller J, et al (2006). NAD(P)H:Quinone Oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev, 15, 979-87.
  4. Chen H, Lum A, Seifried A, et al (1999). Association of the NAD (P) H: Quinone oxidoreductase 609CT polymorphism with a decreased lung cancer risk. Cancer Res, 59, 3045-8.
  5. Chen J, Lin Y, Zhang R, et al (2012). Contribution of NAD(P)H quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and risk of colorectal adenoma and colorectal cancer in Caucasians: a meta-analysis. Arch Med Res, 43, 58-66.
  6. Guha N, Chang JS, Chokkalingam AP, et al (2008). NQO1 polymorphisms and de novo childhood leukemia: a HuGE review and meta-analysis. Am J Epidemiol, 168, 1221-32.
  7. Hamajima N, Matsuo K, Iwata H, et al (2002). NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol, 7, 103-8.
  8. Haruya K, Nobuyuki H, Akiko T, et al (2003). Triplex polymerase chain reactions with confronting two-pair primers (PCR-CTPP) for NQO1 C609T, GSTM1 and GSTT1 polymorphisms: a convenient genotyping method.
  9. Hou L, Chatterjee N, Huang W, et al (2005). CYP1A1 Val462 and NQO1 Ser187 polymorphisms, cigarette use and risk for colorectal adenoma. Carcinogenesis, 26, 1122-8.
  10. Kolesar JM, Dahlberg SE, Marsh S, et al (2011). The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. Oncol Rep, 25, 1765-72.
  11. Larson RA, Wang X, Banerjee M, et al (1999). Prevalence of the inactivating 609C to T polymorphism in the NAD(P) H: quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood, 94, 803-7.
  12. Lewis SJ, Cherry NM, Niven RM, et al (2001). Polymorphisms in theNAD( P)H: quinine oxidoreductase gene and small cell lung cancer risk in a UK population. Lung Cancer, 34, 177-83.
  13. Mei-Miao C, Ying-Ju K, Ann-Ping T, et al (2009). Analysis of NQO1 polymorphisms and p53 protein expression in patients with hepatocellular carcinoma. Histol Histopathol, 24, 1223-32.
  14. Menashe I, Figueroa JD, Garcia-Closas M, et al (2012). Largescale pathwaybased analysis of bladder cancer genome-wide association data from five studies of European background. PLoS One, 7, 29396.
  15. Nebert DW, Roe AL, Vandale SE, et al (2002). NAD (P) H:quinine oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet Med, 4, 62-70.
  16. Ren JJ, OuYang XH, Su XL (2006). NAD (P)H:quinone oxidoreductase gene polymorphism association with gastric carcinoma. Zhong Hua Zhong liu Fang Zhi Za Zhi (in Chinese), 22, 1686-8.
  17. Ross D (2004). NQO1. Atlas genet cytogenet oncol haematol. URL :
  18. Rosvold EA, McGlynn KA, Lustbader ED, et al (1995). Identification of an NAD (P) H: quinone oxidor - eductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics, 5, 199.
  19. Sarmanova J, Susova S, Gut I, et al (2004). Breast cancer: role of polymorphisms in biotransformation enzymes. Eur J Hum Gen, 12, 848-54.
  20. Schulz WA, Krummeck A, Rosinger I, et al (1997). Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics, 7, 235-9.
  21. Siegel D, Anwar A, Winski SL, et al (2001). Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD (P)H:quinone oxidoreductase 1. Mol Pharmacol, 59, 263-8.
  22. Su XL, Yan MR, Yang L, et al (2012). NQO1 C609T polymorphism correlated to colon cancer risk in farmers from western region of Inner Mongolia. Chin J Cancer Res, 24, 317-322.
  23. Traver RD, Siegel D, Beall HD, et al (1997). Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer, 75, 69-75.
  24. Wiemels JL, Pagnamenta A, Taylor GM, et al (1999). United Kingdom Childhood Cancer Study Investigators. A lack of a functional NAD(P)H: quinine oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. Cancer Res, 59, 4095-9.
  25. Xu LL, Wain JC, Miller DP, et al (2001). The NAD (P) H: quinone Oxidoreductase 1 Gene Polymorphism and Lung Cancer Differential Susceptibility Based on Smoking Behavior. Cancer Epidemiol Biomarkers Prev, 10, 303-9.
  26. Yuan W, Xu L, Chen W, et al (2011). Evidence on the association between NQO1 Pro187Ser polymorphism and breast cancer risk in the current studies: a meta-analysis. Breast Cancer Res Treat, 125, 467-72.

Cited by

  1. Association Between Polymorphisms of Metabolic Enzyme Genes and Chromosomal Damage in Benzene-Exposed Workers in China vol.59, pp.11, 2017,